✨ Free AI Report
Metagenomi Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Metagenomi Therapeutics, Inc.
Company Research

Metagenomi Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA...

Analyst-debate audio for Metagenomi Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Metagenomi Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

High-risk, high-reward genome editing play with strong analyst sentiment and meaningful clinical catalysts ahead, though backed...

Read the full analyst-debate transcript →
Industry Genetic Medicines & Gene Editing
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Metagenomi Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Metagenomi Therapeutics, Inc. Overview

Pro stress-test →

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company is advancing in vivo gene-editing therapies toward clinical development.

Strategic Profile

Pro stress-test →

The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products. Its lead program MGX-001 targets hemophilia A with clinical development targeted for 2026.

Competitive Landscape

Pro stress-test →

Metagenomi competes in the emerging in vivo gene editing space against companies like Caribou Biosciences, Prime Medicine, and Sangamo Therapeutics. The company differentiates through its comprehensive metagenomics-derived toolbox covering multiple editing modalities (nucleases, base editors, prime editors, integration systems). Partnerships with Ionis and Affini-T expand addressable market and reduce execution risk.

Industry Context

Metagenomi Therapeutics, Inc. operates in Genetic Medicines & Gene Editing.

Key facts

Founded: 2016 · Headquarters: Emeryville, California · Revenue: $52.3M (2024) · Market cap: $64.2M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Metagenomi Therapeutics, Inc..

  • Lead program MGX-001 for hemophilia A showed sustained Factor VIII activity in nonhuman primates with durable response through ~19 months
  • Recently renamed to Metagenomi Therapeutics (Feb 2026) reflecting strategic focus on later-stage preclinical assets
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Metagenomi Therapeutics name change announced; highlighting strategic focus on advanced gene-editing capabilities
  • Dec 2025Pre-IND meeting held in Q4 2025; company preparing for regulatory interactions
  • +2 moreTrack every material event for Metagenomi Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Metagenomi Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Caribou BiosciencesIn vivo gene editing for hemophilia and other genetic disorders→Prime MedicinePrime editing platform for genetic medicine→Sangamo TherapeuticsZinc finger nuclease-based gene editing therapies→

Compare Metagenomi Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Metagenomi Therapeutics, Inc. operates in Genetic Medicines & Gene Editing. See how the rest of the sector scores on the Cyborg framework.

Browse Genetic Medicines & Gene Editing research →
NEW · MCP server

Ask your AI assistant about Metagenomi Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Metagenomi Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Metagenomi Therapeutics, Inc. do this quarter?”
“Is Metagenomi Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Metagenomi Therapeutics, Inc. do?+
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA...
What is Metagenomi Therapeutics, Inc.'s Cyborg Score?+
Metagenomi Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Metagenomi Therapeutics, Inc.'s main competitors?+
Named competitors include Caribou Biosciences, Prime Medicine, Sangamo Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Metagenomi Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Metagenomi Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Metagenomi Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.